Stocks in news: Infosys, IndusInd Bank, Eternal, Adani Green, Dr Reddy's

Markets remained under pressure on Wednesday and ended lower amid weak global cues and persistent geopolitical concerns. Technically, the Nifty has slipped below the immediate support level of 24,000, and the close suggests the possibility of a retest of the 23,650–23,800 zone in the near term. On the upside, analysts say the 24,150–24,300 region is expected to act as stiff resistance on any rebound. Despite the weakness in the benchmark index, rotational buying across sectors continues to offer ample stock-specific trading opportunities.

In today's trade, shares of Infosys, IndusInd Bank, Eternal, Adani Green, Dr Reddy's among others will be in focus due to various news developments and first quarter results.

Read more: Pre-market action: Here's the trade setup for today's session

Private lender IndusInd Bank reported 72% year-on-year (YoY) growth in its consolidated net profit at Rs 1,037 crore in the first quarter. The same stood at Rs 604 crore in the last year quarter. Net Interest Income (NII) in Q1 was flat at Rs 4,685 crore as compared to Rs 4,640 crore in the same quarter of last year.

Food delivery giant Eternal on Wednesday reported a consolidated net profit of Rs 92 crore in the first quarter of financial year 2027, marking an 268% increase from Rs 25 crore posted in the same period last year. The net profit is attributable to the owners of the parent company.

BPCL

BPCL on Wednesday reported a standalone loss of Rs 3,962 in the first quarter. The company had reported a profit of Rs 6,124 crore in the last year quarter. Revenue from operations in the reporting period increased 23% YoY to Rs 1.59 lakh crore.

Adani Green reported 19% year-on-year (YoY) growth in its consolidated net profit at Rs 845 crore in the first quarter. The same stood at Rs 713 crore in the last year quarter. Revenue from operations in the reporting period increased 16% YoY to Rs 4,663 crore.

Indian drugmaker Dr Reddy's reported a smaller-than-expected quarterly profit on Wednesday, as muted sales of a key generic oncology drug and pricing pressure weighed on the competitive US market. Consolidated net profit tanked 69% to Rs 444 crore ($45.98 million) in the first quarter ending June 30.